Document is current
Any future updates will be listed below
-
Authors
Peters, Daniel T.
Hatfield, Jess
Reese, Mollie
Zeidner, Joshua F.
-
Funding
Funding for this research was provided by:
National Institute of General Medical Sciences (T32GM086330)
- License Information
-
More Information
Article History
Received: 30 December 2025
Accepted: 31 December 2025
First Online: 17 March 2026
Declarations
:
: D.T.P. has received honoraria for advisory boards from Syndax.J.F.Z. has served as a consultant for AbbVie, Astellas, AstraZeneca, Crossbow Therapeutics, Daiichi Sankyo, Foghorn, Genmab, Ipsen, Jazz, Johnson & Johnson, Kura Oncology, Neogenomics, Novartis, Relmada Therapeutics, Rigel, Sellas Life Sciences, Servier, Shattuck Labs, Sumitomo Pharma, and Syndax; and has received grant support outside of this work from AbbVie, Akesobio Pharma, Aptevo Therapeutics, Arog, Ascentage, AstraZeneca, Auron Therapeutics, Daiichi Sankyo, Faron, Jazz, Lin Biosciences, Loxo, Merck, Newave, Novartis, Sellas Life Sciences, Shattuck Labs, Stemline, Sumitomo Pharma, and Zentalis.
